HIV

FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard therapies in suppressed adults.

Sweeping federal funding cuts and stalled prevention efforts are unraveling hard-won gains in HIV research and access, warns Peter Staley.

Todd Brown, MD, PhD, explains key considerations for using GLP‑1 drugs in patients with HIV, including titration tips, surgery precautions, and bone/muscle monitoring.

Presentations focused on the efficacy of long-acting cabotegravir, doravirine/islatravir, and bictegravir/lenacapavir when used as antiretroviral therapy.

Abstracts presented during the Conference on Retroviruses and Opportunistic Infections 2026 offered a glimpse into which therapies patients prefer to use to treat HIV.

At CROI 2026, experts warned that missing HBV screening risks reactivation during HIV therapy switches.

The REPRIEVE study finds statins cut heart events in HIV by lowering lipids, inflammation, and hypertension risk.

A session at CROI 2026 opened with questions on how glucagon-like peptide-1 receptor agonists could be used in HIV.

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for remission without therapy.

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to improve testing and treatment access.

New research shows that adherence to antiretroviral therapy and pre-exposure prophylaxis depends on a steady budget through PEPFAR and SNAP.

Posters presented during the Conference on Retroviruses and Opportunistic Infections 2026 highlight the safe use of tirzepatide in patients with HIV.

The first full day of CROI 2026 featured a lecture that outlined the next steps in treating and preventing HIV.

The conference, held in Denver, Colorado, promises presentations on breaking research and the future of prevention.

Medicare HIV cases are projected to double by 2035, with cumulative costs reaching $195.6 billion and creating critical challenges for federal funding.

The most-read content for HIV focused on funding cuts to HIV aid and research and satisfaction with telemedicine for HIV care.

Our top conference coverage of the year highlighted findings presented at CROI 2025, ACCC Spring, and EHA, among others.

The past year has seen multiple changes in the HIV space that have long-term effects when it comes to ending the epidemic.

Top content from CROI 2025 focused on COVID-19 and HIV, including the safety of a vaccine in people taking antiretroviral therapy.

Although a cure is likely still a ways off, continuing to pursue long-acting injectable treatments and PrEP is key to reducing cases of HIV.

Lenacapavir and cabotegravir are among the most important advancements in HIV prevention and treatment within the past 10 years.

The HIV chatbot was noninferior in increasing self-testing compared with the real-time support by human administrators.

Individuals told their absolute risk of HIV had higher interest in pre-exposure prophylaxis (PrEP) compared with those told relative risk.

Men who have sex with men (MSM) expressed interest in both monthly oral pills and injections every 6 months to prevent HIV.

Topline results find that single-tablet regimen of bictegravir/lenacapavir had noninferior efficacy when patients switched from multitablet regimens in HIV.